Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Diabetes Care
; 36(9): 2559-65, 2013 Sep.
Article
em En
| MEDLINE
| ID: mdl-23645886
ABSTRACT
OBJECTIVE:
To evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in subjects with type 2 diabetes. RESEARCH DESIGN ANDMETHODS:
We conducted a randomized, two-stage, 24-week, open-label, phase 2 study in type 2 diabetes inadequately controlled with metformin. Stage I 155 subjects were randomized to 20 or 40 µg/day of ITCA 650 or Ex-BID 5 â 10 µg. Stage II 131 subjects were rerandomized to 20, 40, 60, or 80 µg/day of ITCA 650. Change from baseline for HbA1c, weight, and fasting plasma glucose were evaluated at weeks 12 and 24.RESULTS:
HbA1c was significantly lower in all groups after 12 and 24 weeks. Stage I mean change in HbA1c from a mean baseline of 7.9-8.0% was -0.98, -0.95, and -0.72% for the 20 and 40 µg/day ITCA 650 and Ex-BID groups, respectively, with 63, 65, and 50% of subjects achieving HbA1c levels ≤ 7% (P < 0.05). Stage II significant (P < 0.05) reductions in HbA1c (≈ 1.4% from baseline) were achieved with 60 and 80 µg/day ITCA 650, and 86 and 78% of subjects achieved HbA1c ≤ 7% at 24 weeks; respectively. Weight was reduced by 2.8-3.7 kg (P < 0.05) at 24 weeks in all except the 20 â 20 µg/day group. ITCA 650 was well tolerated; nausea was lower and transient with 20 µg/day relative to Ex-BID; and 60 µg/day had the best profile of tolerability and HbA1c lowering.CONCLUSIONS:
ITCA 650 significantly reduced HbA1c and weight and was well tolerated. The 20 â 60 µg/day regimen was considered the best dose for further examination in phase 3.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Peçonhas
/
Diabetes Mellitus Tipo 2
/
Hipoglicemiantes
/
Metformina
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article